mFOLFOX + bevacizumab

mFOLFOX + bevacizumab is a combination therapy regimen used for the treatment of metastatic colorectal cancer (mCRC). The regimen consists of the mFOLFOX chemotherapy backbone—comprising oxaliplatin (a platinum-based DNA cross-linking agent), leucovorin (calcium folinate, a biochemical modulator), and 5-fluorouracil (an antimetabolite thymidylate synthase inhibitor)—and bevacizumab, a humanized monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A) to suppress tumor angiogenesis. In the clinical trial context associated with Yanqiao Zhang (e.g., NCT06144190), this combination is utilized as a standard-of-care backbone in conjunction with the investigational PD-1/CTLA-4 bispecific antibody aipalolitovorelizumab (QL1706) for the first-line treatment of patients with microsatellite stable (MSS) or proficient mismatch repair (pMMR) metastatic colorectal cancer harboring the BRAF V600E mutation.

Brand names

Eloxatin

Other names

FOLFOX + bevacizumab5-FU + leucovorin + oxaliplatin + bevacizumab